NTRP News Alert Neurotrope Inc. (NTRP) 1.2500 02/15/2015 06:
Post# of 64108
Posted On: 02/15/2015 7:15:51 AM
Neurotrope Inc. (NTRP) 1.2500 $NTRP
Neurotrope Forms Clinical Advisory Board to Support Alzheimer's Disease Program
PR Newswire - Wed Jan 14, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced the formation of its Alzheimer's Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, MD, ScD, CCF, Martin R. Farlow, MD, Sam Gandy, MD, PhD, Christina Sampaio, MD, PhD, and Michael Weiner, MD, among others.
Neurotrope to Present at the Biotech Showcase 2015 Conference
PR Newswire - Wed Jan 07, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced it is scheduled to present at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 - 14, 2015.
IPOs and Transactions Week in Review: December 1 - 5
PR Newswire - Tue Dec 09, 9:30AM CST
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
IPWR: 8.24 (+0.25)
Neurotrope Announces Last Patient Dosed in Phase 2a Clinical Trial of Bryostatin-1 for Alzheimer's Disease
PR Newswire - Thu Nov 20, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) announced today that the last patient has been dosed in its Phase 2a clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The trial is being conducted under an Investigational New Drug (IND) application filed by the Company's licensor, the Blanchette Rockefeller Neuroscience Institute (BRNI).
Neurotrope Appoints Warren W. Wasiewski, M.D. as Executive Vice President, Development and Chief Medical Officer
PR Newswire - Thu Nov 06, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that Warren W. Wasiewski, M.D., F.A.A.P. has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President, Development and Chief Medical Officer, effective immediately. Dr. Wasiewski replaces Dr. Richard Scheyer, who had served as Chief Medical Officer since January 2014.
ALXN: 182.29 (+6.02)
Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors
PR Newswire - Thu Sep 18, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment of Larry D. Altstiel, M.D., Ph.D. to the Company's Board of Directors, effective September 12, 2014. The appointment of Dr. Altstiel fills a vacancy on the Board of seven members. Dr. Altstiel will also become Chairman of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees of the Board. He is also a member of Neurotrope's Scientific Advisory Board, a position he has held since October 2013.
Neurotrope To Host Conference Call
PR Newswire - Wed Aug 20, 12:30PM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that it will host a conference call to provide an update on Company activities.
Neurotrope Forms Clinical Advisory Board to Support Alzheimer's Disease Program
PR Newswire - Wed Jan 14, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced the formation of its Alzheimer's Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, MD, ScD, CCF, Martin R. Farlow, MD, Sam Gandy, MD, PhD, Christina Sampaio, MD, PhD, and Michael Weiner, MD, among others.
Neurotrope to Present at the Biotech Showcase 2015 Conference
PR Newswire - Wed Jan 07, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced it is scheduled to present at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 - 14, 2015.
IPOs and Transactions Week in Review: December 1 - 5
PR Newswire - Tue Dec 09, 9:30AM CST
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
IPWR: 8.24 (+0.25)
Neurotrope Announces Last Patient Dosed in Phase 2a Clinical Trial of Bryostatin-1 for Alzheimer's Disease
PR Newswire - Thu Nov 20, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) announced today that the last patient has been dosed in its Phase 2a clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The trial is being conducted under an Investigational New Drug (IND) application filed by the Company's licensor, the Blanchette Rockefeller Neuroscience Institute (BRNI).
Neurotrope Appoints Warren W. Wasiewski, M.D. as Executive Vice President, Development and Chief Medical Officer
PR Newswire - Thu Nov 06, 7:30AM CST
Neurotrope, Inc. (OTCQB: NTRP) today announced that Warren W. Wasiewski, M.D., F.A.A.P. has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President, Development and Chief Medical Officer, effective immediately. Dr. Wasiewski replaces Dr. Richard Scheyer, who had served as Chief Medical Officer since January 2014.
ALXN: 182.29 (+6.02)
Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors
PR Newswire - Thu Sep 18, 7:30AM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment of Larry D. Altstiel, M.D., Ph.D. to the Company's Board of Directors, effective September 12, 2014. The appointment of Dr. Altstiel fills a vacancy on the Board of seven members. Dr. Altstiel will also become Chairman of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees of the Board. He is also a member of Neurotrope's Scientific Advisory Board, a position he has held since October 2013.
Neurotrope To Host Conference Call
PR Newswire - Wed Aug 20, 12:30PM CDT
Neurotrope, Inc. (OTCQB: NTRP) today announced that it will host a conference call to provide an update on Company activities.
(0)
(0)Scroll down for more posts ▼